Colorectal and Ovarian Cancer Patients With Liver Metastases Clinical Trial
Official title:
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy
This study is intended to test an experimental drug called EMD 525797 (Abituzumab). This
drug is not yet approved for sale and has only been tested in a small number of people to
date (prior to this study starting another research study was carried out involving 37
healthy volunteers receiving the study drug). Until more is known about this study drug, it
can only be used in research studies.
This research study is planned to answer important questions about how the study drug is
tolerated and how it may work in subjects with ovarian and colorectal cancer which has
spread to the liver (i.e. metastatic cancer). The Sponsor (Merck KGaA) of this study is
developing the study drug.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment